User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Zoledronic acid for treatment of Paget's disease of bone.

Primary tabs

Devogelaer, Jean-Pierre [UCL] Manicourt, Daniel [UCL]

Paget's disease of bone is characterised by a focal increase in bone resorption and bone formation. This anarchic metabolism leads to disorganised bone, with bone pain, fragility, deformity and compression of the peripheral or CNS according to the involved site. Quality of life of sufferers is dramatically impaired. Symptomatic therapy trends to relieve pain, but cannot seek to prevent other complications. Only 'specific' therapy can fulfil this purpose. Bisphosphonates have become the cornerstone for therapy of Paget's disease in the last 25 years. Progressively stronger bisphosphonates have been launched on the market. The last drug available, zoledronic acid, the most potent of this drug family, can be administered intravenously. It possesses a long-acting efficacy, allowing a follow up on a yearly basis and permitting the chance of a very long remission of the Pagetic lesion. In the long term, prevention of severe complications can be envisaged, with a reasonable pharmacoeconomic cost.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2007
Journal information "Expert Opinion on Pharmacotherapy" - Vol. 8, no. 16, p. 2863-2869 (2007)
Peer reviewed yes
Publisher Informa Healthcare (London)
issn 1465-6566
e-issn 1744-7666
Publication status Publié
Affiliations UCL - MD/MINT - Département de médecine interne
UCL - (SLuc) Service de rhumatologie
MESH Subject Animals ; Bone Density Conservation Agents - therapeutic use ; Clinical Trials as Topic ; Diphosphonates - therapeutic use ; Humans ; Imidazoles - therapeutic use ; Osteitis Deformans - drug therapy - epidemiology
Keywords Bisphosphonate ; Paget's disease of bone ; Pharmacoeconomy ; Therapy ; Zoledronic acid
Links
  1. Van Staa T. P., Selby P., Leufkens H. G. M., Lyles K., Sprafka J. M., Cooper C., Incidence and Natural History of Paget's Disease of Bone in England and Wales, 10.1359/jbmr.2002.17.3.465
  2. Langston A. L., Campbell M. K., Fraser W. D., MacLennan G., Selby P., Ralston S. H., , Clinical Determinants of Quality of Life in Paget’s Disease of Bone, 10.1007/s00223-006-0184-2
  3. Beyens Greet, Daroszewska Anna, de Freitas Fenna, Fransen Erik, Vanhoenacker Filip, Verbruggen Leon, Zmierczak Hans-Georg, Westhovens René, Van Offel Jan, Ralston Stuart H, Devogelaer Jean-Pierre, Van Hul Wim, Identification of Sex-Specific Associations Between Polymorphisms of the Osteoprotegerin Gene, TNFRSF11B, and Paget's Disease of Bone, 10.1359/jbmr.070333
  4. Basle M. F., Fournier J. G., Rozenblatt S., Rebel A., Bouteille M., Measles Virus RNA Detected in Paget's Disease Bone Tissue by in situ Hybridization, 10.1099/0022-1317-67-5-907
  5. BARKER, BMJ, 1, 1181 (1977)
  6. Cooper Cyrus, Schafheutle Karen, Dennison Elaine, Kellingray Samantha, Guyer Peter, Barker David, The Epidemiology of Paget's Disease in Britain: Is the Prevalence Decreasing?, 10.1359/jbmr.1999.14.2.192
  7. Doyle T, Gunn J, Anderson G, Gill M, Cundy T, Paget’s disease in New Zealand: evidence for declining prevalence, 10.1016/s8756-3282(02)00876-1
  8. Cundy H. R., Gamble G., Wattie D., Rutland M., Cundy T., Paget?s Disease of Bone in New Zealand: Continued Decline in Disease Severity, 10.1007/s00223-004-0281-z
  9. RAPADO, J. Bone Miner. Res., 14, S96 (1999)
  10. Gennari Luigi, Di Stefano Marco, Merlotti Daniela, Giordano Nicola, Martini Giuseppe, Tamone Cristina, Zatteri Roberto, De Lucchi Roberto, Baldi Carlo, Vattimo Angelo, Capoccia Silvia, Burroni Luca, Geraci Simone, De Paola Vincenzo, Calabrò Anna, Avanzati Annalisa, Isaia Giancarlo, Nuti Ranuccio, Prevalence of Paget's Disease of Bone in Italy, 10.1359/jbmr.050518
  11. Ralston Stuart H, Afzal Muhammad A, Helfrich Miep H, Fraser William D, Gallagher James A, Mee Andrew, Rima Bert, Multicenter Blinded Analysis of RT-PCR Detection Methods for Paramyxoviruses in Relation to Paget's Disease of Bone, 10.1359/jbmr.070103
  12. MALDAGUE, Clin. Orthop., 217, 126 (1987)
  13. Devogelaer Jean-Pierre, Modern Therapy for Paget??s Disease of Bone : Focus on Bisphosphonates, 10.2165/00024677-200201040-00006
  14. Green Jonathan R., Rogers Michael J., Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption, 10.1002/ddr.10071
  15. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G.G., Ebetino F.H., Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite, 10.1016/j.bone.2005.05.003
  16. Viereck Volker, Emons Günter, Lauck Vanessa, Frosch Karl-Heinz, Blaschke Sabine, Gründker Carsten, Hofbauer Lorenz C., Bisphosphonates Pamidronate and Zoledronic Acid Stimulate Osteoprotegerin Production by Primary Human Osteoblasts, 10.1006/bbrc.2002.6510
  17. Arden-Cordone M., Siris E. S., Lyles K. W., Knieriem A., Newton R. A., Schaffer V., Zelenakas K., Antiresorptive Effect of a Single Infusion of Microgram Quantities of Zoledronate in Paget's Disease of Bone, 10.1007/s002239900255
  18. Buckler H, Fraser W, Hosking D, Ryan W, Maricic M.J, Singer F, Davie M, Fogelman I, Birbara C.A, Moses A.M, Lyles K, Selby P, Richardson P, Seaman J, Zelenakas K, Siris E, Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study, 10.1016/s8756-3282(99)00071-x
  19. Reid Ian R., Miller Paul, Lyles Kenneth, Fraser William, Brown Jacques P., Saidi Youssef, Mesenbrink Peter, Su Guoqin, Pak Judy, Zelenakas Ken, Luchi Monica, Richardson Peter, Hosking David, Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease, 10.1056/nejmoa044241
  20. PATEL, . J. Bone Miner. Res., 8, 1467 (1993)
  21. Devogelaer J. P., Brown J. P., Burckhardt P., Meunier P. J., Goemaere S., Lippuner K., Body J. J., Samsioe G., Felsenberg D., Fashola T., Sanna L., Ortmann C. E., Trechsel U., Krasnow J., Eriksen E. F., Garnero P., Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis, 10.1007/s00198-007-0367-3
  22. Black Dennis M., Delmas Pierre D., Eastell Richard, Reid Ian R., Boonen Steven, Cauley Jane A., Cosman Felicia, Lakatos Péter, Leung Ping Chung, Man Zulema, Mautalen Carlos, Mesenbrink Peter, Hu Huilin, Caminis John, Tong Karen, Rosario-Jansen Theresa, Krasnow Joel, Hue Trisha F., Sellmeyer Deborah, Eriksen Erik Fink, Cummings Steven R., Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis, 10.1056/nejmoa067312
  23. Hosking David, Lyles Kenneth, Brown Jacques P, Fraser William D, Miller Paul, Curiel Manuel Diaz, Devogelaer Jean-Pierre, Hooper Michael, Su Guoqin, Zelenakas Ken, Pak Judy, Fashola Taiwo, Saidi Youssef, Eriksen Erik Fink, Reid Ian R, Long-Term Control of Bone Turnover in Paget's Disease With Zoledronic Acid and Risedronate, 10.1359/jbmr.061001
  24. LECOMTE, Value Health, 8, A73 (2005)
  25. Hewitt R. E., Lissina A., Green A. E., Slay E. S., Price D. A., Sewell A. K., The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins, 10.1111/j.1365-2249.2005.02665.x
  26. Markowitz Glen S., Fine Paul L., Stack Jay I., Kunis Cheryl L., Radhakrishnan Jai, Palecki Winicjusz, Park Jin, Nasr Samih H., Hoh Shirley, Siegel David S., D'Agati Vivette D., Toxic acute tubular necrosis following treatment with zoledronate (Zometa), 10.1046/j.1523-1755.2003.00071.x
  27. Alvarez L., Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment, 10.1093/rheumatology/keh185
  28. WOITGE, Clin. Chem., 46, 684 (2000)
  29. Reid Ian R, Davidson James S, Wattie Diana, Wu Fiona, Lucas Jenny, Gamble Gregory D, Rutland Michael D, Cundy Tim, Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone, 10.1016/j.bone.2004.03.023
  30. McClung Michael R., Lewiecki E. Michael, Cohen Stanley B., Bolognese Michael A., Woodson Grattan C., Moffett Alfred H., Peacock Munro, Miller Paul D., Lederman Samuel N., Chesnut Charles H., Lain Douglas, Kivitz Alan J., Holloway Donna L., Zhang Charlie, Peterson Mark C., Bekker Pirow J., Denosumab in Postmenopausal Women with Low Bone Mineral Density, 10.1056/nejmoa044459
Bibliographic reference Devogelaer, Jean-Pierre ; Manicourt, Daniel. Zoledronic acid for treatment of Paget's disease of bone.. In: Expert Opinion on Pharmacotherapy, Vol. 8, no. 16, p. 2863-2869 (2007)
Permanent URL http://hdl.handle.net/2078.1/11162